1. Home
  2. Medical News
  3. Modern Aesthetics RMD
advertisement

Dr. Bianca Viscomi Discusses Rethinking Menopausal Skin Aging

Key Takeaways

  • Menopause alters the biological environment of the skin, affecting fibroblast activity, collagen production, dermal thickness, elasticity, and tissue resilience.

  • Calcium hydroxylapatite (CaHA), the active component of RADIESSE, can provide structural support and stimulate extracellular matrix remodeling, with treatment approaches varying according to dilution and injection depth.

  • Bianca Viscomi, MD, emphasized individualized, long-term treatment strategies that prioritize skin quality and tissue health rather than exclusively correcting visible signs of aging.

Radiesse Global Longevity Summit
11/20/2026

Menopause represents more than an acceleration of visible skin aging. The hormonal changes accompanying this transition alter the biological environment of the skin, affecting collagen production, fibroblast activity, and tissue resilience, according to Bianca Viscomi, MD.

During her keynote presentation, "Rethinking Skin Aging in Menopause: Evidence and Experience with RADIESSE," at the RADIESSE Global Longevity Summit, Dr. Viscomi explored the biological changes associated with menopause and the potential role of calcium hydroxylapatite (CaHA) in addressing age-related changes in skin structure and quality.

In an interview with Modern Aesthetics, Dr. Viscomi explained that declining estrogen levels influence several processes responsible for maintaining skin integrity, including collagen synthesis, dermal thickness, elasticity, and hydration.

"Menopause doesn't simply accelerate skin aging," she said. "It will change the biological environment in which aging is already occurring."

Central to these changes are fibroblasts, which produce collagen and other extracellular matrix components while helping maintain the structural and mechanical properties of the dermis. As estrogen levels decline, alterations in this environment can contribute to reduced firmness, diminished tissue resilience, and impaired healing capacity.

Dr. Viscomi emphasized that understanding these biological changes is essential to distinguishing menopausal skin from skin aging associated with chronological age alone.

CaHA and Extracellular Matrix Remodeling in Menopausal Skin

Dr. Viscomi described how CaHA, marketed as RADIESSE by Merz Aesthetics, can address different aspects of facial aging depending on its formulation and placement.

Undiluted CaHA provides structural support when injected into deeper tissue planes, while diluted or hyperdiluted formulations are used to target skin quality through fibroblast-mediated extracellular matrix remodeling.

According to Dr. Viscomi, available research has demonstrated increased deposition of collagen, elastin, and other extracellular matrix components following CaHA treatment. However, the extent to which menopausal status influences these responses remains an area of ongoing investigation.

In her clinical practice, she reported observing improvements in skin firmness, facial support, pigmentation, and overall tissue quality among patients receiving CaHA treatments.

"What I appreciate the most is the possibility of achieving progressive natural-looking improvements without excessive volumization," she said.

She also reported observing favorable responses among menopausal patients who were not receiving hormone therapy, although she acknowledged that additional research is needed to better understand treatment outcomes in this population.

For menopausal patients, Dr. Viscomi favors an individualized, multilayer approach that combines deeper structural support with more superficial treatments targeting skin quality. She pays particular attention to the lateral face and jawline, where tissue laxity may become more apparent, and sometimes combines CaHA with energy-based treatments such as Ultherapy.

Her approach prioritizes biological and structural skin characteristics over chronological age alone.

Moving Beyond Anti-Aging Toward Skin Longevity

Looking ahead, Dr. Viscomi described a broader shift in aesthetic medicine from correcting visible signs of aging toward preserving skin health and function over time.

She characterized biostimulatory treatments as one component of a comprehensive strategy that also includes skincare, photoprotection, lifestyle considerations, hormonal health, and other aesthetic interventions.

Dr. Viscomi also discussed the importance of beginning preventive strategies before perimenopause, identifying approximately age 35 as a potential starting point for considering longer-term aesthetic treatment planning, while emphasizing that skincare, sun protection, and healthy lifestyle practices can begin earlier.

Although clinical experience supports the use of CaHA for certain aesthetic outcomes, evidence specifically evaluating its long-term effects in menopausal and postmenopausal populations remains an important area for further study.

"I think the key message is that we should stop treating menopausal skin as simply older skin and signs of age," Dr. Viscomi said. "The final goal is skin health and skin longevity, and the aesthetic outcome will be a consequence."

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free